Compoundingsemaglutidecompoundingbiosimilarspharmacosimilars

Cureus authors propose ABCDE checklist for judging semaglutide copies

The commentary argues SUSTAIN, STEP and SELECT evidence does not transfer to synthetic or compounded versions sharing the semaglutide name.

By Maren Holt · Senior Reporter, GLP-1

Aug 20 20:00 ETSource: Cureus

The wire

01The analysis sets out five domains for comparing reference recombinant semaglutide with generics, biosimilars and compounded copies: approved status, bioavailability, consistency, drug-device performance and evidence.
02Pharmacists and prescribers weighing compounded or synthetic semaglutide get a structured way to raise impurity, aggregation and multidose-vial dosing-error concerns.
03The framework is an author-proposed conceptual checklist, not validated guidance, and the piece offers no head-to-head comparability data.

Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications
Cureus · 2026 Aug · Mohan V, Kalra S, Ahluwalia A et al.